Compare COLL & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | LWLG |
|---|---|---|
| Founded | 2002 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Containers/Packaging |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.3M | 625.9M |
| IPO Year | 2015 | 2011 |
| Metric | COLL | LWLG |
|---|---|---|
| Price | $24.83 | $3.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $44.88 | $9.00 |
| AVG Volume (30 Days) | 613.1K | ★ 3.6M |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.79 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $780,567,000.00 | $236,855.00 |
| Revenue This Year | $6.73 | N/A |
| Revenue Next Year | $1.37 | $998.56 |
| P/E Ratio | $39.01 | ★ N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $21.43 | $2.84 |
| 52 Week High | $50.79 | $18.71 |
| Indicator | COLL | LWLG |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 37.32 |
| Support Level | $21.67 | $3.14 |
| Resistance Level | $26.39 | $5.61 |
| Average True Range (ATR) | 0.85 | 0.46 |
| MACD | 0.17 | -0.05 |
| Stochastic Oscillator | 61.74 | 10.05 |
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.